Bailard Inc. bought a new position in shares of Epizyme Inc (NASDAQ:EPZM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $251,000.
Several other hedge funds have also recently bought and sold shares of the company. NEA Management Company LLC boosted its stake in shares of Epizyme by 3.2% during the 3rd quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock worth $123,079,000 after acquiring an additional 200,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Epizyme by 6.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock worth $51,640,000 after acquiring an additional 200,982 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Epizyme by 0.4% during the 4th quarter. Jennison Associates LLC now owns 1,875,528 shares of the biopharmaceutical company’s stock worth $23,538,000 after acquiring an additional 7,867 shares in the last quarter. State Street Corp boosted its stake in shares of Epizyme by 59.6% during the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after acquiring an additional 658,727 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Epizyme during the 3rd quarter worth about $17,591,000. 86.09% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Roth Capital assumed coverage on shares of Epizyme in a research note on Thursday, February 1st. They set a “buy” rating and a $24.00 target price on the stock. Oppenheimer set a $26.00 price target on shares of Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research downgraded shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.33.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.05. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. analysts predict that Epizyme Inc will post -2.23 earnings per share for the current year.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 25.20% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This news story was reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/14/bailard-inc-purchases-shares-of-20000-epizyme-inc-epzm/1890582.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.